SCHEMBL4359457

SCHEMBL4359457

Oc1c(Cl)cc(NC(=S)Nc2ccc(C(F)(F)F)cc2)cc1Cl

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.57
ALDH1A1 P00352 5/20 0.57
NPSR1 Q6W5P4 3/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
CDK1 P06493 1/20 0.51
MAOB P27338 2/20 0.51
MEN1 O00255 6/20 0.50
KMT2A Q03164 6/20 0.50
HTT P42858 4/20 0.50
KDM4E B2RXH2 4/20 0.49
GAA P10253 3/20 0.49
TDP1 Q9NUW8 1/20 0.49
SMN1; SMN2 Q16637 5/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C19 P33261 1/20 0.49
LMNA P02545 3/20 0.48
KIF11 P52732 1/20 0.47
CA12 O43570 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4341318 0.86 MAPT (0.59) MAPTALDH1A1NPSR1L3MBTL1CDK1
SCHEMBL10217960 0.86 MAPT (0.76) MAPTALDH1A1NPSR1L3MBTL1CDK1
SCHEMBL4348451 0.86 PDE2A (0.48) MAPTALDH1A1NPSR1L3MBTL1CDK1
SCHEMBL4348880 0.84 EPHX2 (0.69) MAPTMEN1KMT2AHTTCA12
SCHEMBL4354217 0.84 MAPT (0.53) MAPTALDH1A1NPSR1L3MBTL1CDK1
SCHEMBL4357497 0.83 MEN1 (0.61) MAPTALDH1A1NPSR1L3MBTL1CDK1
SCHEMBL9453957 0.83 CDK1 (0.68) MAPTALDH1A1NPSR1L3MBTL1CDK1
SCHEMBL4358929 0.83 CDK1 (0.53) MAPTALDH1A1CDK1MAOBMEN1
SCHEMBL4347956 0.82 ALDH1A1 (0.58) MAPTALDH1A1NPSR1L3MBTL1MAOB
SCHEMBL4353864 0.81 CDK1 (0.51) MAPTALDH1A1NPSR1L3MBTL1CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-1402887-A1 New compounds for the inhibition of undesired cell proliferation and use thereof Jerini AG (DE) 2004-03-31 EP claimed
EP-1402888-A1 The use of substituted carbocyclic compounds as rotamases inhibitors Jerini AG (DE) 2004-03-31 EP claimed
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US disclosed
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US disclosed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US disclosed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US disclosed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US disclosed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN disclosed
EP-1539683-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS Jerini AG (DE) 2005-06-15 EP disclosed
WO-2004030664-A2 NEW COMPOUNDS FOR THE INHIBITION OF UNDESIRED CELL PROLIFERATION AND USE THEREOF JERINI AG (DE) 2004-04-15 WO disclosed
WO-2004026815-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS JERINI AG (DE) 2004-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 MAPT 4439/4885ALDH1A1 2565/4885NPSR1 99/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 MAPT 4184/4885ALDH1A1 2767/4885NPSR1 240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.